Covalent Modifiers

JULY 25, 2024

We have integrated structural and quantitative proteomics with biochemical assays to decipher the mode of action of covalent USP30 inhibition by a small molecule containing a cyanopyrrolidine reactive group, USP30-I-1.

Biochemical Assays 72

Biochemical Assays Small Molecule Treatment Disease 72

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 82

Small Molecule Clinical Trials Drugs Therapies 82

Chemical Biology and Drug Design

JUNE 7, 2023

In the present study, we got the SIRT7 protein structure from Alpha Fold2 Database and performed structure-based virtual screening to develop specific SIRT7 inhibitors using the SIRT7 inhibitor 97,491 interaction mechanism. In our study, we demonstrated that targeting SIRT7 may offer novel therapeutic options for cancer treatment.

Small Molecule 100

Small Molecule Treatment Research 100

Chemical Biology and Drug Design

MAY 11, 2023

Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hyperlipidemia. In discovery of novel small molecules that interfere PCSK9/LDLR protein–protein interaction (PPI), structural modification was performed based on our previously derived compounds.

Small Molecule 100

Small Molecule Treatment Research 100

The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models.

Research 40

Research Clinical Trials Small Molecule Trials 40

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Drug Target Review

APRIL 16, 2024

Can you explain how Radioligand Therapy (RLT) is applicable in the treatment of both chemotherapy-resistant tumours and in naïve patients who have not undergone prior cancer treatment? RLT utilises radiopharmaceuticals, which are compounds consisting of a targeting molecule (ligand) and a radioactive isotope (radionuclide).

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Many cancer treatments target DNA, but often these can cause collateral damage, leading to severe side effects.

Small Molecule 66

Small Molecule RNA DNA Pharmaceutical Companies 66

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. About Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Conversations in Drug Development Trends

MAY 30, 2024

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. The MAA file in the E.U.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

Immune Response 106

Immune Response Therapies Vaccine Small Molecule 106

The Pharma Data

MAY 16, 2022

AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually. “We are proud to present data on a range of digestive conditions across our portfolio and pipeline. .

Disease 40

Disease Small Molecule Treatment Trials 40

The Pharma Data

JANUARY 13, 2021

These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma,” said Michael Bozik, M.D., Knopp expects to present results of the trial at a forthcoming medical meeting. Measuring Eosinophils to Make Treatment Decisions in Asthma.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

SEPTEMBER 28, 2020

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect. We’ve been amazed with just how effective our treatment has been. If humans respond in a similar way, the benefits of treatment are two-fold.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

LifeSciVC

DECEMBER 6, 2022

As Darnell observed, the prospect of being able to regulate Transcription Factor function holds the potential to reframe the way we treat disease but achieving that goal with traditional small molecule screening approaches is impossible. We are rapidly advancing the chemistry required modulate its activity.

Small Molecule 40

Small Molecule DNA Regulations Science 40

Metabolite Tales Blog

JANUARY 23, 2024

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. Enzymes involved include CYP1A2, CYP2C8, CYP3A4, CYP4F2, and aldehyde oxidase (AOX).

Small Molecule 52

Small Molecule FDA Approval FDA Pharmacokinetics 52

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. Sometimes a degradant presents unexpectedly after GLP toxicology studies are completed or are underway. Global regulatory agencies, including the U.S.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

KIF1A

MAY 9, 2023

KIF1A.ORG’s 23rd Research Roundtable meeting, “Structure to Patient Perspective: Vision Loss in KAND” was presented by KIF1A.ORG’s Dr. Dylan Verden. Furthermore, both small molecule and gene therapy treatments that increase BDNF levels reduced neurodegeneration in these models.

Research 52

Research Small Molecule Treatment Science 52

The Pharma Data

DECEMBER 15, 2020

However, natural product drug discovery presents several challenges that have reduced industry interest, including the inability to identify and isolate novel bioactive molecules responsible for a desired effect. Natural products have yielded numerous landmark drugs including aspirin, metformin, morphine and quinine.

Small Molecule 52

Small Molecule Production Laboratories Engineering 52

DrugBank

AUGUST 15, 2024

Financial Implications of High-Level Industry-Academic Collaborations Accelerated Time-to-Market The traditional drug development timeline, which can span over a decade, is a significant obstacle to delivering timely treatments to patients. Past collaborations have already yielded three clinical oncology candidates. One

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

The Pharma Data

DECEMBER 13, 2020

Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma. FDA for the treatment of Cholangiocarcinoma.

Small Molecule 40

Small Molecule FDA Clinical Trials DNA 40

The Open Targets Blog

NOVEMBER 30, 2023

It is presented here with an additional layer of analysis with a drug discovery focus. Pharmacogenetics widget showing genetic variants in CFTR associated with drug response Pharmacogenetics widget showing genetic variants association with the response to Ivacaftor , a small molecule drug indicated for cystic fibrosis.

Pharmacogenetics 59

Pharmacogenetics Small Molecule Disease Drugs 59

KIF1A

JUNE 30, 2023

KAND and Spasticity : We created this resource to help families understand mechanisms of spasticity in KAND, including considerations between different treatment options. With your support, KIF1A.ORG continues to bring together the expertise and innovation needed to rapidly discover treatments and cures for KAND.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

JANUARY 10, 2021

IDE397 program update to be presented at the 39th Annual J.P. IDEAYA Biosciences will present a program update on IDE397 and its broader synthetic lethality pipeline at the 39 th Annual J.P. IDEAYA’s presentation for the 39 th Annual J.P. SOUTH SAN FRANCISCO, Calif. , Morgan Healthcare Conference.

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

FEBRUARY 25, 2022

“Today’s announcement builds on our commitment to broaden access to essential, high-quality and cost-effective treatment options for patients living with certain chronic inflammatory conditions.”. The company anticipates submitting study results for presentation at an upcoming medical congress.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

LifeSciVC

MARCH 1, 2023

Importantly, they also pointed to something that we at HotSpot Therapeutics and a small group of other researchers and companies recognized several years ago – that scientific advances have made this attractive, but once considered ‘undruggable,’ target druggable. The timing could not better for this review put forward by the UPMC team.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Premier Consulting Blog

AUGUST 8, 2024

Typically, new drug development under the 505(b)(2) pathway requires less capital and time and has a higher success rate versus the 505(b)(1) pathway, where the Sponsor develops safety and effectiveness information from scratch.

Pharmacokinetics 52

Pharmacokinetics Drugs FDA Production 52

The Pharma Data

AUGUST 30, 2021

The study will allow assessment of any difference in efficacy that may persist at month 6 of treatment. The proportion of patients experiencing serious adverse events, severe adverse events, and adverse events leading to study discontinuation were similar in both treatment arms. About Abrocitinib.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative diseases and have the chance to improve the lives of millions of patients drastically.”.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

Here, FDA breaks our concentration from strength in the context of self-evident bioequivalence that would allow FDA to grant a biowaiver (requiring inactive ingredients to be present in the same concentration as the Reference Listed Drug), which is only narrowly applicable. mL) in addition to Original Concentration Humira.” mL, 20 mg/0.4

FDA 59

FDA Biosimilars Production Regulations 59

Drug Target Review

NOVEMBER 22, 2023

How does iOnctura plan to design novel combination treatments that effectively target both autotaxin and the TGF pathway while ensuring safety for patients? We will present some of the data at the end of the study at an international conference next year. Are there any unique strategies or approaches being considered?

Licensing 52

Licensing Licensing Small Molecule Therapies 52

The Pharma Data

MARCH 29, 2022

The researchers, including at UBC, Université de Sherbrooke, and Cornell University, believe this is the first treatment of its kind proven to be effective against all COVID-19 variants of concern reported to date, including alpha, beta, gamma and delta. The small molecule was developed by Drs.

Virus 52

Virus Small Molecule Research Clinical Trials 52

Drug Target Review

JANUARY 5, 2024

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. Among the 13 N. 7 Figure 2: Structural model of the chosen N.

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59

The Pharma Data

MARCH 23, 2022

(NYSE: PFE) today announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). Participants received etrasimod 2mg once daily.

Trials 52

Trials Small Molecule Biosimilars Therapies 52